Stock listing
NASDAQ:TRAX First Tracks Biotherapeutics, Inc. Stock
Home listing (NASDAQ) of First Tracks Biotherapeutics, Inc.
Follow First Tracks Biotherapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TRAX
$45.08 USD -0.15 (-0.3%)
Close on Oct 30, 2026
- Day range
- $43.36 – $45.87 USDOct 30, 2026
- Volume
- 434,124 sharesOct 30, 2026
- Market cap
- $1.89B USDAt the close on Oct 30, 2026 · price × 42.02M shares outstanding
- Traded on an average day
- $32.54M USDMedian day 643,231 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TRAX · Home | $45.08 USD | -0.145 (-0.3%) | 434,124 | $45.03 | $45.87 | $43.36 | $45.23 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:TRAX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $45.08 | -0.145 | -0.3% | $45.03 | $45.87 | $43.36 | 434,124 | |
| $45.23 | -0.495 | -1.1% | $46.18 | $47.55 | $44.05 | 471,526 | |
| $45.72 | +0.34 | +0.7% | $44.84 | $46.37 | $44.79 | 640,962 | |
| $45.38 | +1.90 | +4.4% | $43.90 | $46.08 | $43.27 | 617,731 | |
| $43.48 | -0.57 | -1.3% | $43.10 | $45.42 | $41.83 | 592,253 | |
| $44.05 | +0.91 | +2.1% | $43.13 | $44.78 | $41.60 | 849,800 | |
| $43.14 | +0.37 | +0.9% | $42.27 | $44.14 | $41.67 | 844,300 | |
| $42.77 | +1.52 | +3.7% | $41.20 | $42.89 | $40.00 | 711,500 | |
| $41.25 | +4.97 | +13.7% | $36.67 | $41.78 | $36.28 | 1,033,400 | |
| $36.28 | +1.82 | +5.3% | $35.01 | $37.26 | $35.00 | 1,434,200 | |
| $34.46 | -1.58 | -4.4% | $37.07 | $37.24 | $33.38 | 1,041,400 | |
| $36.04 | +1.91 | +5.6% | $34.69 | $36.30 | $33.99 | 1,578,500 | |
| $34.13 | +2.45 | +7.7% | $31.28 | $34.32 | $30.88 | 982,100 | |
| $31.68 | -2.37 | -7.0% | $33.72 | $34.36 | $31.12 | 1,112,300 | |
| $34.05 | +2.20 | +6.9% | $39.45 | $40.50 | $33.02 | 7,310,200 | |
| $31.85 | -0.16 | -0.5% | $31.96 | $33.28 | $30.71 | 855,200 | |
| $32.01 | +1.42 | +4.6% | $33.31 | $33.31 | $30.11 | 1,483,400 | |
| $30.59 | -0.80 | -2.5% | $30.91 | $31.75 | $30.53 | 355,500 | |
| $31.39 | -1.60 | -4.8% | $33.02 | $33.02 | $30.96 | 613,800 | |
| $32.99 | -0.29 | -0.9% | $34.44 | $34.44 | $30.88 | 667,800 | |
| $33.28 | -0.64 | -1.9% | $34.45 | $35.41 | $32.50 | 1,167,900 | |
| $33.92 | -1.52 | -4.3% | $35.20 | $36.03 | $33.77 | 564,100 | |
| $35.44 | -0.54 | -1.5% | $36.74 | $37.31 | $35.32 | 610,600 | |
| $35.98 | -0.67 | -1.8% | $36.61 | $36.80 | $34.99 | 645,500 | |
| $36.65 | +2.23 | +6.5% | $34.40 | $37.24 | $33.55 | 674,500 | |
| $34.42 | -1.41 | -3.9% | $35.82 | $35.82 | $33.66 | 356,500 | |
| $35.83 | -0.83 | -2.3% | $36.11 | $37.09 | $34.57 | 1,144,100 | |
| $36.66 | -4.37 | -10.7% | $41.14 | $41.38 | $36.57 | 658,400 | |
| $41.03 | +2.04 | +5.2% | $39.43 | $42.24 | $39.37 | 893,200 | |
| $38.99 | +0.39 | +1.0% | $38.87 | $39.92 | $38.04 | 661,300 | |
| $38.60 | -0.60 | -1.5% | $40.20 | $41.48 | $38.45 | 2,590,700 | |
| $39.20 | +0.20 | +0.5% | $39.91 | $41.90 | $39.13 | 554,800 | |
| $39.00 | +0.53 | +1.4% | $40.25 | $40.89 | $38.57 | 637,200 | |
| $38.47 | +0.90 | +2.4% | $37.22 | $39.02 | $35.98 | 526,000 | |
| $37.57 | +1.13 | +3.1% | $36.17 | $38.50 | $36.17 | 442,600 | |
| $36.44 | -1.54 | -4.1% | $38.08 | $38.30 | $35.49 | 619,900 | |
| $37.98 | -1.59 | -4.0% | $39.35 | $40.69 | $37.40 | 389,100 | |
| $39.57 | -2.23 | -5.3% | $40.74 | $42.79 | $39.31 | 478,600 | |
| $41.80 | +1.34 | +3.3% | $39.45 | $43.78 | $39.20 | 540,700 | |
| $40.46 | -2.05 | -4.8% | $41.06 | $42.00 | $40.38 | 456,200 | |
| $42.51 | -2.77 | -6.1% | $44.57 | $45.56 | $42.29 | 717,000 | |
| $45.28 | +4.11 | +10.0% | $44.48 | $47.98 | $44.26 | 1,365,300 | |
| $41.17 | -0.67 | -1.6% | $41.57 | $42.62 | $40.75 | 557,500 | |
| $41.84 | -0.02 | 0.0% | $41.67 | $42.44 | $39.83 | 687,000 | |
| $41.86 | -2.88 | -6.4% | $44.36 | $44.74 | $41.69 | 410,000 | |
| $44.74 | +0.55 | +1.2% | $44.09 | $45.39 | $43.80 | 375,300 | |
| $44.19 | -0.92 | -2.0% | $45.84 | $45.84 | $43.73 | 561,700 | |
| $45.11 | +1.83 | +4.2% | $43.27 | $46.48 | $43.27 | 441,929 | |
| $43.28 | +0.17 | +0.4% | $43.47 | $44.64 | $42.56 | 677,251 | |
| $43.11 | +1.21 | +2.9% | $42.98 | $44.79 | $40.72 | 528,000 | |
| $41.90 | -3.60 | -7.9% | $45.50 | $45.99 | $41.78 | 478,200 | |
| $45.50 | +1.62 | +3.7% | $45.25 | $46.64 | $43.84 | 810,500 | |
| $43.88 | +0.28 | +0.6% | $43.76 | $45.71 | $43.11 | 724,700 | |
| $43.60 | -0.44 | -1.0% | $43.85 | $44.80 | $42.75 | 509,700 | |
| $44.04 | +0.01 | 0.0% | $43.46 | $45.35 | $42.41 | 446,200 | |
| $44.03 | -2.10 | -4.6% | $46.15 | $46.79 | $43.00 | 715,100 | |
| $46.13 | -0.62 | -1.3% | $46.54 | $48.35 | $46.00 | 407,000 | |
| $46.75 | -1.17 | -2.4% | $48.94 | $49.91 | $46.47 | 613,600 | |
| $47.92 | +2.59 | +5.7% | $45.71 | $48.49 | $44.90 | 708,800 | |
| $45.33 | +0.02 | 0.0% | $45.93 | $46.72 | $44.82 | 629,300 | |
| $45.31 | -1.64 | -3.5% | $47.25 | $47.98 | $44.95 | 443,700 | |
| $46.95 | +0.94 | +2.0% | $46.99 | $47.96 | $44.67 | 939,900 | |
| $46.01 | -0.15 | -0.3% | $46.21 | $49.58 | $45.74 | 690,000 | |
| $46.16 | +2.12 | +4.8% | $43.49 | $47.00 | $42.05 | 259,600 | |
| $44.04 | -3.74 | -7.8% | $47.70 | $47.70 | $43.53 | 869,700 | |
| $47.78 | +5.91 | +14.1% | $42.78 | $48.00 | $42.50 | 970,100 |
- Ticker
- NASDAQ:TRAX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 15, 2026
First Tracks Biotherapeutics Announces $200 Million Private Placement
Latest deck · Oct 13, 2026
Investor Presentation (October 2026)
Investor deck · 51 slides
Latest news
First Tracks Biotherapeutics Announces $200 Million Private Placement
Oct 15, 2026
Closed $36.04 (+5.6%) on Oct 15, 2026
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
Oct 12, 2026
Closed $34.05 (+6.9%) on Oct 12, 2026
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
Oct 11, 2026
Closed $34.05 (+6.9%) on Oct 12, 2026
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
Aug 26, 2026
Closed $44.74 (+1.2%) on Aug 27, 2026
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Aug 12, 2026
Closed $44.03 (-4.6%) on Aug 13, 2026
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
May 21, 2026
Closed $17.18 (+2.5%) on May 22, 2026
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Closed $16.90 (-6.9%) on May 15, 2026
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
Apr 20, 2026
Closed $18.60 (-17.4%) on Apr 20, 2026
Financings
Private placement of shares of common stock
Oct 15, 2026
Announced: about US$200M · US$32.75 a share · Leerink Partners +3
Dealers: Leerink Partners, Piper Sandler, UBS Investment Bank, Wells Fargo Securities
Buyers: Affinity Asset Advisors, LLC; First Light Asset Management; Sirenia Capital Management LP; TCGX; Trails Edge Capital Partners; Vestal Point Capital
Use of proceeds: General corporate purposes, including clinical development of ANB033, a CD122 antagonist
Decks
Investor Presentation (October 2026)
Investor deck · 51 slides · Oct 13, 2026
First Tracks Biotherapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 8 in all · newest Oct 15, 2026 · oldest 2026
- Decks
- 1 deck · latest Oct 13, 2026
Where First Tracks Biotherapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TRAX · Home listing · This page | NASDAQ | United States | USD |
| BMV:TRAX | BMV | Mexico | MXN |
| BOATS:TRAX | BOATS | United States | USD |
| BIVA:TRAX | BIVA | Mexico | MXN |
| Dusseldorf:B43 | Dusseldorf | Germany | USD |
| Hamburg:B43 | Hamburg | Germany | EUR |
Log in to ask 6ix AI your own questions about First Tracks Biotherapeutics, Inc.